Table 3.
IDH mutation | Fluorescence visibility | 5-ALA dose | Margin type | Tumor type | |
---|---|---|---|---|---|
Yes | No | None | Weak | Strong | Single | Double | ST | IZ | RABT | ||
Pilocytic Astrocytoma | – | 3 | 0 | 0 | 3 | 2 | – | 5 |
Diffuse Astrocytoma | 52 | 0 | 39 | 6 | 7 | 37 | 15 | – | 52 |
Anaplastic Astrocytoma | 24 | 0 | 3 | 1 | 20 | – | 0 | 0 | 10 | 34 |
Glioblastoma | 0 | 123 | 11 | 9 | 116 | – | 124 | 57 | 74 | 393 |
Oligodendroglioma | 21 | 0 | 11 | 6 | 4 | 17 | 4 | – | 21 |
Ganglioglioma | – | 2 | 2 | 0 | – | – | 4 |
Anaplastic Oligodendroglioma | 4 | 0 | 0 | 4 | 0 | – | – | 4 |
The numbers result from the availability of the data. Each biopsy yielded, on average, 481 spectra (250 to 740 interquartile range). Respective administrations of a single dose (n = 10, 20 mg/kg b.w.) and a double dose (n = 13, 40 mg/kg b.w.) of 5-ALA were carried out.